Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.55 |
| ▸ | CMA1 | P23946 | 4/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23832967 | 1.00 | ACE (0.55) | ACECMA1F2PRSS1SIRT2 | |
| SCHEMBL30192889 | 0.94 | KLK5 (0.52) | ACECMA1F2PRSS1SIRT2 | |
| SCHEMBL23845539 | 0.86 | ACE (0.54) | ACECMA1F2PRSS1KLK5 | |
| SCHEMBL6078614 | 0.83 | ACE (0.61) | ACECMA1F2PRSS1KLK5 | |
| SCHEMBL6078759 | 0.83 | ACE (0.61) | ACECMA1F2PRSS1KLK5 | |
| SCHEMBL27015288 | 0.83 | ACE (0.47) | ACEF2ACE2 | |
| SCHEMBL29401183 | 0.83 | SIRT2 (0.53) | ACESIRT2 | |
| SCHEMBL9959535 | 0.83 | SIRT2 (0.53) | ACESIRT2 | |
| SCHEMBL5349888 | 0.83 | SIRT2 (0.53) | ACESIRT2 | |
| SCHEMBL5900836 | 0.82 | ACE (0.77) | ACECMA1F2PRSS1KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| CN-115776891-A | STAT degradants and uses thereof | 凯麦拉医疗公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-4121055-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188696-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | ACE 206/4885CMA1 875/4885F2 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.